Published in Cancer on February 15, 1995
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53
Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer (1997) 1.40
[Resection of solitary liver metastases of malignant melanoma]. Chirurg (1995) 1.39
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.36
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) (2007) 1.35
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol (2011) 1.34
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res (1997) 1.29
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res (1995) 1.28
Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res (2000) 1.28
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer (1997) 1.28
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods (1997) 1.27
Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis (1997) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res (1995) 1.19
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods (2001) 1.15
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia (2004) 1.10
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol (2006) 1.10
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol (2011) 1.08
Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol (1993) 1.08
Lipopolysaccharide effectively up-regulates B7-1 (CD80) expression and costimulatory function of human monocytes. Scand J Immunol (1995) 0.98
HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res (1994) 0.95
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol (2006) 0.95
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer (2011) 0.93
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol (2002) 0.93
The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol (2011) 0.92
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol (2006) 0.92
Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. J Immunol Methods (2001) 0.91
Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother (2000) 0.91
Expression of the stem cell marker nestin in peripheral blood of patients with melanoma. Br J Dermatol (2010) 0.90
T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res (1996) 0.90
Differential expression and functional behaviour of the alpha v and beta 3 integrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthritis and osteoarthritis in vitro. Ann Rheum Dis (1997) 0.89
Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. Eur J Cancer (2003) 0.89
Minimal residual disease in melanoma. Semin Surg Oncol (2001) 0.88
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol (2014) 0.88
The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin alpha(v)beta(3) expression. Int J Cancer (2001) 0.88
Role of TGF-β in melanoma. Curr Pharm Biotechnol (2011) 0.86
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol (1992) 0.85
High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer (2000) 0.85
Detection of clonally rearranged T-cell-receptor gamma chain genes from T-cell malignancies and acute inflammatory rheumatic disease using PCR amplification, PAGE, and automated analysis. Ann Hematol (1997) 0.83
Regulation of interleukin-8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor-alpha and interferon-gamma. Melanoma Res (1996) 0.83
Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother Emphasis Tumor Immunol (1994) 0.82
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol (2004) 0.81
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie (2004) 0.81
Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR. Melanoma Res (2001) 0.81
Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother Emphasis Tumor Immunol (1996) 0.81
Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res (1998) 0.81
Nested quantitative real time PCR for detection of occult tumor cells. Recent Results Cancer Res (2001) 0.81
Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. Cancer Immunol Immunother (1994) 0.81
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2007) 0.80
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs (2013) 0.80
[Simultaneous squamous cell carcinoma and follicular lymphoma of the tonsil]. HNO (2010) 0.79
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol (2015) 0.79
Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology (2011) 0.79
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. Eur J Cancer (1996) 0.79
Internal control for quality assurance of diagnostic RT-PCR. Biotechniques (1998) 0.78
Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol (2001) 0.78
Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer (2000) 0.78
UV-induced N-ras mutations are T-cell targets in human melanoma. Melanoma Res (1997) 0.78
[Current role for induction chemotherapy in head and neck tumors]. Laryngorhinootologie (2008) 0.78
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. Cancer Chemother Pharmacol (2004) 0.77
Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer (1993) 0.77
A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer. Chemotherapy (2007) 0.76
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy. Melanoma Res (1995) 0.76
Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer (1994) 0.76
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. Leuk Lymphoma (1999) 0.76
A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J Immunol Methods (1996) 0.75
What can we learn from phase II adjuvant trials in melanoma? Br J Cancer (2000) 0.75
Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci (1986) 0.75
Rheumatic disease following immunotherapy. Ann Rheum Dis (1993) 0.75
Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Onkologie (1990) 0.75
[Chilblain lupus erythematosus. A case report]. Internist (Berl) (1992) 0.75
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma. Int J Cancer (1999) 0.75
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol (2012) 0.75
Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood (1989) 0.75
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol (2011) 0.75
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol (2009) 0.75
The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer. Eur J Cancer (2002) 0.75
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol (2010) 0.75
[Results with the use of the M-2 protocol in plasmacytoma]. Dtsch Med Wochenschr (1986) 0.75
Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone). Hematol Oncol (2007) 0.75
[Interleukin 2: immunologic background and clinical use in tumor therapy]. Hautarzt (1990) 0.75
Monitoring of circulating tumor cells in a patient with synchronous metastatic melanoma and colon carcinoma. Ann Oncol (2010) 0.75
Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Ann Oncol (2001) 0.75
[Repetitive immuno-embolization of inoperative liver metastases of renal cell carcinoma. Method characterization and preliminary results]. Urologe A (1996) 0.75
[Diagnosis of and therapy for choroidal melanoma]. Klin Monbl Augenheilkd (2013) 0.75
[Side effects and complications of intra-arterial tumor therapy--experiences with 577 interventions]. Rontgenpraxis (1995) 0.75
[Primary malignant non-Hodgkin lymphoma of the uterus]. Geburtshilfe Frauenheilkd (1989) 0.75
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Ann Surg Oncol (2001) 0.75
[Choroid melanoma. Adjuvant therapy in high risk patients and new therapy approaches in the metastatic stage]. Ophthalmologe (2002) 0.75